QHP Capital Closes $1.1B Single-Asset Continuation Vehicle for Azurity Pharmaceuticals

Transaction Overview QHP Capital, L.P. has announced the closing of a $1.1 billion single-asset continuation vehicle (CV) for Azurity Pharmaceuticals, Inc. The transaction was led by HarbourVest Partners, with Pantheon Ventures, L.P. participating as a significant investor. Audax Strategic Capital (ASC) also participated through a separate structured growth investment and as a syndicate investor in the CV. Structure & LP Options The CV offered existing limited partners in QHP's selling fund a binary choice: realize strong returns through a cash exit, or roll proceeds into the new Continuation Vehicle to maintain exposure to Azurity's continued value creation. The transaction saw broad participation from existing QHP LPs, with many electing to roll. Lead investor: HarbourVest Partners Co-investors: Pantheon Ventures, Audax Strategic Capital Deal size: $1.1 billion Asset: Azurity Pharmaceuticals — specialty pharma focused on overlooked patient populations Strategic Rationale The new capital will support Azurity's organic growth, business development, licensing activities, and potential strategic M&A. QHP expressed strong conviction in Azurity's management team and long-term strategy. "This CV reflects our strong conviction in Azurity's strategy and leadership. We are pleased to partner with HarbourVest as lead investor alongside Pantheon and Audax Strategic Capital." — Jeff Edwards, Partner at QHP Capital HarbourVest's participation is notable given the firm's simultaneous launch of its dedicated Private Equity Continuation Solutions (PECS) fund, signaling aggressive buildout of its GP-led secondaries capabilities. Why This Matters for Private Markets This $1.1B healthcare CV underscores the maturation of the GP-led secondary market: blue-chip secondaries firms are now competing to lead high-quality single-asset transactions in defensible, cash-generative sectors like specialty pharma. For LPs evaluating GP-led opportunities, the combination of HarbourVest and Pantheon as lead investors provides strong quality signaling. For sellers in secondary markets, this deal sets a pricing benchmark for healthcare continuation vehicles in Q1 2026.